Qiagen (QGEN) Q2 2026 Earnings Call Transcript
Qiagen (QGEN) reported Q2 2026 adjusted diluted EPS of $0.62 at constant exchange rates, above its outlook of at least $0.60. Growth pillars rose 5% at CER, with Sample Technologies up 9% CER and QIAcuity delivering double-digit growth. Adjusted operating income was $157 million (29.4% margin). Operating cash flow was $301 million for 6 months, and the company increased its 2026 dividend 40% to $0.35.
How this was made
The 30-second read
Why it matters
Traders can update expectations for Qiagen’s 2026 earnings power and capital return after a Q2 EPS beat, reaffirmed guidance, and a 40% dividend increase, while monitoring disclosed weakness in U.S. immigration testing and certain respiratory-related products.
Market read
The transcript contains multiple concrete, decision-relevant datapoints: EPS beat vs outlook at CER, reaffirmed full-year outlook, and a sizable dividend increase, alongside specific segment headwinds.
What to watch
Inventory build for new product launches (higher days inventory) could affect near-term working capital dynamics and future gross margin if demand timing shifts.
Background
This is a Q2 2026 earnings call transcript for Qiagen, covering segment performance, profitability, cash flow, capital returns, and full-year outlook.
Ticker impact
Qiagen reported Q2 2026 adjusted diluted EPS of $0.62 at CER above outlook, reaffirmed full-year 2026 outlook, and raised the 2026 dividend 40%.
Likely positive bias for the next session and into guidance-follow-through, but expect volatility around the disclosed U.S. immigration testing demand decline.
The transcript provides multiple decision-relevant datapoints: EPS beat vs outlook, reaffirmed full-year outlook, and a concrete capital return action (40% dividend increase). Offsetting negatives include declines in diagnostic solutions, QIAstat-Dx, PCR/nucleic acid amplification, and U.S. immigration testing demand.
Market effects
Signals continued demand resilience in sample preparation and digital PCR/consumables, while certain testing categories (immigration, respiratory) remain pressured.
Americas and EMEA show mixed performance, with China down in the low teens but sequential improvement.
Reinforces biotech tools and diagnostics demand patterns, with cash generation and capital return remaining central to investor positioning.
Counterpoint
The EPS beat may be partly mix and efficiency-driven, while underlying volume softness in immigration and respiratory testing could reassert pressure in coming quarters.
Key entities
- companyQiagen
Reported Q2 2026 results, reaffirmed full-year outlook, and increased the annual dividend by 40% in 2026.
